<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men - Fisher, E - 2014 | Cochrane Library</title> <meta content="The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men - Fisher, E - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006744.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men - Fisher, E - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006744.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006744.pub3" name="dc.identifier" scheme="DOI"/> <meta content="The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men" name="citation_title"/> <meta content="Euan Fisher" name="citation_author"/> <meta content="Academic Urology Unit" name="citation_author_institution"/> <meta content="Kesavapillai Subramonian" name="citation_author"/> <meta content="University Hospital Birmingham" name="citation_author_institution"/> <meta content="Muhammad Imran Omar" name="citation_author"/> <meta content="m.i.omar@abdn.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD006744.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006744.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006744.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006744.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Device Removal; Acute Disease; Adrenergic alpha‐Antagonists [adverse effects, *therapeutic use]; Doxazosin [therapeutic use]; Indoles [therapeutic use]; Quinazolines [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Recovery of Function [drug effects]; Sulfonamides [adverse effects, therapeutic use]; Tamsulosin; Urinary Catheterization [*instrumentation]; Urinary Retention [*therapy]; Urination [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006744.pub3&amp;doi=10.1002/14651858.CD006744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006744\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006744\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006744.pub3",title:"The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men",firstPublishedDate:"Jun 10, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Incontinence Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006744.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006744.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006744.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006744.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006744.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006744.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006744.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006744.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006744.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006744.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10124 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006744.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/appendices#CD006744-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/table_n/CD006744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/table_n/CD006744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#CD006744-cr-0002">Euan Fisher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#CD006744-cr-0003">Kesavapillai Subramonian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information#CD006744-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Muhammad Imran Omar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information/en#CD006744-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006744.pub3">https://doi.org/10.1002/14651858.CD006744.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006744-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006744-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006744-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006744-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006744-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006744-abs-0003">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006744-abs-0001" lang="en"> <section id="CD006744-sec-0001"> <h3 class="title" id="CD006744-sec-0001">Background</h3> <p>Acute urinary retention is a urological emergency in men and requires urgent catheterisation. Any intervention which aims at improving urinary symptoms following an acute urinary retention episode could be potentially beneficial. Alpha blockers relax prostatic smooth muscle cells thereby decreasing the resistance to urinary flow and by doing so could improve urinary symptoms. </p> </section> <section id="CD006744-sec-0002"> <h3 class="title" id="CD006744-sec-0002">Objectives</h3> <p>To assess the effectiveness of alpha blockers on successful resumption of micturition following removal of a urethral urinary catheter after an episode of acute urinary retention in men. In the absence of internationally agreed outcome measures for the success of a trial without catheter, success was defined as the return to satisfactory voiding without need for re‐catheterisation within 24 hours. </p> </section> <section id="CD006744-sec-0003"> <h3 class="title" id="CD006744-sec-0003">Search methods</h3> <p>We searched the Cochrane Incontinence Group Specialised Trials Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE in process, and handsearching of journals and conference proceedings (searched 9 October 2013), CENTRAL (2013, Issue 5) (searched 5 June 2013), MEDLINE 1946 to May Week 4 2013, MEDLINE in Process (covering to 3 June 2013), EMBASE Classic and EMBASE 1947 to 2013 Week 22 (all searched 4 June 2013) and the reference lists of relevant articles. No language or other restrictions were imposed on the searches. </p> </section> <section id="CD006744-sec-0004"> <h3 class="title" id="CD006744-sec-0004">Selection criteria</h3> <p>Only randomised and quasi‐randomised clinical trials of alpha blockers for trial without a urethral catheter following an episode of acute urinary retention in men were included. </p> </section> <section id="CD006744-sec-0005"> <h3 class="title" id="CD006744-sec-0005">Data collection and analysis</h3> <p>Two review authors independently examined all the citations and abstracts derived from the search strategy. Any disagreement about trial selection and inclusion was resolved by discussion. A third independent judgement was sought where disagreement persisted. Two review authors extracted independently, cross‐checked and processed the data as described in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i>. Quality of evidence of the critical outcomes was assessed by adopting the GRADE approach. </p> </section> <section id="CD006744-sec-0006"> <h3 class="title" id="CD006744-sec-0006">Main results</h3> <p>Nine randomised clinical trials were included in this review. Eight trials compared alpha blockers versus placebo (five trials tested alfuzosin and two trials tested tamsulosin, one trial tested both alfuzosin and tamsulosin, one trial tested silodosin) and one trial compared an alpha blocker (doxazosin) versus no treatment. Trial without catheter was performed after treatment with the drug for one to three days in seven trials and for eight and 32 days in two other trials respectively. There was moderate quality evidence to suggest that the rate of successful trial without catheter favoured alpha blockers over placebo ( 366/608, 60.2%, of men using an alpha blocker were able to void spontaneously after catheter removal compared with 185/486, 38.1%, using placebo, risk ratio (RR) 1.55, 95% confidence interval (CI) 1.36 to 1.76). The incidence of recurrent acute urinary retention was lower in groups treated with an alpha blocker (RR 0.69, 95% CI 0.60 to 0.79). This evidence was of moderate quality and was statistically significant for alfuzosin, tamsulosin and silodosin, though not for doxazosin. Of the trials mentioning adverse effects (for example, postural hypotension, dizziness), there was not enough information to detect statistically significant differences between the groups (RR 1.19, 95% CI 0.75 to 1.89) and the evidence was of low quality. Overall, adverse effect rates were low for both placebo and alpha blockers and, for example, vasodilatation‐related adverse effects did not often result in discontinuation. However, the data in this review are limited due to the large amount of unpublished data that was not available to us. </p> </section> <section id="CD006744-sec-0007"> <h3 class="title" id="CD006744-sec-0007">Authors' conclusions</h3> <p>There was some evidence to suggest that alpha blockers increase the success rates of trial without catheter, and the incidence of adverse effects was low. There was some evidence of a decreased incidence of acute urinary retention. The need for further surgery, cost effectiveness and recommended duration of alpha blocker treatment after successful trial without catheter remain unknown as these were not reported by any trial. There is a lack of internationally agreed outcome measures for what constitutes successful trial without catheter. This makes meta‐analysis difficult. Large, well‐designed controlled trials, which use the recommendations set out in the CONSORT statement, and include clinically important outcome measures, are required. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006744-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006744-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006744-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006744-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006744-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006744-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006744-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006744-abs-0004" lang="en"> <h3>Alpha blocker treatment for men to increase chances to have urinary catheter successfully removed </h3> <p><b><i>Background on the condition</i> </b> </p> <p>Acute urinary retention in men is a medical emergency characterised by the sudden and often painful inability to pass urine. There are many known causes including prostate obstruction (because of enlargement of the prostate or cancer), urethral strictures (a narrowing of the urethra due to scar tissue), urine infection, constipation and neurological conditions. A narrow drainage tube (urinary catheter) is temporarily inserted into the bladder through the penis to allow drainage of urine. Once the catheter is removed, some men fail to pass urine again and need to be re‐catheterised. In these men, continued use of catheters or prostate surgery are the standard treatment options. Catheters are associated with risks such as infection and can harm quality of life. Measures for increasing the rate of successful catheter removal, that is, enabling patients to urinate spontaneously again, are therefore potentially beneficial. Alpha blockers (for example tamsulosin, alfuzosin) are a group of drugs known to have positive effects on urinary symptoms such as poor urinary flow. It is believed that their relaxing effect on the prostate may also increase the chance to void again after catheter removal. This review evaluated the evidence available to support this practice. </p> <p><b><i>The main findings of the review</i> </b> </p> <p>In nine clinical trials men were either given a dummy tablet (placebo, inactive drug), an alpha blocker for one to three days (in one study up to a maximum of eight days and in another for 32 days) or no treatment before the catheter was removed. In ideal circumstances, neither patients nor doctors knew which type of tablet was given, to prevent the bias in reporting the results. The results suggested that alpha blocker treatment increased the chances of successful catheter removal and return to urination although the overall scientific evidence available to support this was limited. Four different alpha blockers were tested (alfuzosin, tamsulosin, doxazosin and silodosin). Their results were similar except for doxazosin which did not seem to make a significant difference. </p> <p><b><i>Adverse effects</i> </b> </p> <p>Side effects caused by alpha blockers were few and comparable to placebo or no treatment, though this evidence was limited. They included retrograde ejaculation, dizziness, low blood pressure, fainting, sleepiness, feeling unwell and headache. </p> <p><b><i>Conclusions</i> </b> </p> <p>There was some evidence to say that alpha blockers also reduce the risk of suffering another (recurrent) episode of urinary retention after successful catheter removal, though it remains unclear whether they reduce the need for future surgery on the prostate. It is therefore unclear whether, or for how long, alpha blocker treatment should be continued after successful catheter removal and whether the costs of alpha blocker treatment in such situations are justified. Further research is needed to answer these questions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006744-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006744-sec-0093"></div> <h3 class="title" id="CD006744-sec-0094">Implications for practice</h3> <section id="CD006744-sec-0094"> <p>Results from this review suggest that administration of an alpha blocker during trial without catheter (TWOC) for adult men catheterised for acute urinary retention may be of benefit in decreasing rates of recurrent acute urinary retention relative to control. The incidence of adverse effects appears to be low. However, the data in this review are limited due to the large amount of unpublished data that was not available to us (<a href="./references#CD006744-bbs2-0045" title="RamirezJ . Expression of concern about tamsulosin: over three quarters of human studies are unpublished. figshare2014. [DOI: http://dx.doi.org/10.6084/m9.figshare.1094338] ">Ramirez 2014</a>). </p> </section> <h3 class="title" id="CD006744-sec-0095">Implications for research</h3> <section id="CD006744-sec-0095"> <p>There is an urgent need for standardisation of the definition of what constitutes a successful TWOC for future studies. More randomised controlled trials are needed to assess whether alpha blocker treatment is beneficial for successful TWOC, prevents recurrent urinary retention and whether it reduces the need for prostatic surgery. Furthermore, long‐term follow‐up studies in which patients with successful TWOC are maintained on the allocated intervention are needed to determine if they are worthwhile in the longer term. Other questions to be answered are cost effectiveness and the duration of alpha blocker treatment after TWOC. </p> <p>As the majority of the identified trails were single centred, therefore, future trials should be large, adequately powered and multi‐centred. The trials should include outcomes which are critical from patients' perspective and which should also abide by the principles and recommendations of the CONSORT guideline. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006744-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006744-sec-0029"></div> <div class="table" id="CD006744-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blocker versus placebo or control for acute urinary retention in adult men</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alpha blocker versus placebo or control for acute urinary retention in adult men</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> acute urinary retention in adult men<br/> <b>Intervention:</b> Aalpha blocker versus placebo or control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aalpha blocker versus placebo or control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ability to void spontaneously after TWOC without the need for re‐catheterisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b> <br/> (1.36 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1044<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>582 per 1000</b> <br/> (509 to 666) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of recurrent urinary retention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.69</b> <br/> (0.60 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1023<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> <br/> (304 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for prostatic surgery</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Condition‐specific QoL</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost effectiveness</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number with adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.2</b> <br/> (0.74 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>657<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (55 to 145) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; QoL: quality of life; <b>TWOC</b>: trial without catheter </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Random sequence generation unclear in 4 studies and high risk in 1 study. Allocation concealment unclear in 6 studies and high risk in 1 study.<br/> <sup>2</sup> A minimum of ten trials are required to assess for publication bias.<br/> <sup>3</sup> Random sequence generation unclear in 3 studies and high risk in 1 study. Allocation concealment unclear in 5 studies and high risk in 1 study.<br/> <sup>4</sup> Wide 95% confidence interval: RR 1.20 (95% CI 0.74 to 1.95) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006744-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006744-sec-0030"></div> <section id="CD006744-sec-0031"> <h3 class="title" id="CD006744-sec-0031">Description of the condition</h3> <p>According to International Continence Society, urinary retention is defined as the inability to pass urine despite persistent effort (<a href="./references#CD006744-bbs2-0034" title="HaylenBT , deRidderD , FreemanRM , SwiftSE , BerghmansB , LeeJ , et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics2010;29:4‐20. ">Haylen 2010</a>). Acute urinary retention in men is a urological emergency. It is characterised by a sudden and often very painful inability to pass urine. The standard first‐line management is bladder catheterisation (insertion of a drainage tube into the bladder). Reported incidence rates of acute urinary retention vary from 0.4% to 25% per year in men seen in urological practice every year (<a href="./references#CD006744-bbs2-0048" title="SchulmanCC . Long‐term aspects of medical treatment of BPH. European Urology2001;40 Suppl 3:8‐12. ">Schulman 2001</a>). One large US cohort study estimated the risk of a retention episode at 23% for a 60‐year old male if he lived for another 20 years (<a href="./references#CD006744-bbs2-0036" title="JacobsenSJ , JacobsenDJ , GirmanCJ , RobertsRO , RhodesT , GuessHA . Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology1997;158:481‐7. ">Jacobsen 1997</a>). The incidence of acute urinary retention in the overall male population is low. It increases with age and various studies have reported incidence rates ranging from 2.2 to 6.8 out of 1000 man‐years in the general male population (<a href="./references#CD006744-bbs2-0036" title="JacobsenSJ , JacobsenDJ , GirmanCJ , RobertsRO , RhodesT , GuessHA . Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology1997;158:481‐7. ">Jacobsen 1997</a>; <a href="./references#CD006744-bbs2-0039" title="MeigsJB , BarryMJ , GiovannucciE , RimmEB , StampferMJ , KawachiI . Incidence rates and risk factors for acute urinary retention: the health professionals followup study. Journal of Urology1999;162:376‐82. ">Meigs 1999</a>; <a href="./references#CD006744-bbs2-0050" title="TemmlC , BrossnerC , SchatzlG , PonholzerA , KnoeppL , MadersbacherS . The natural history of lower urinary tract symptoms over five years. European Urology2003;43:374‐80. ">Temml 2003</a>; <a href="./references#CD006744-bbs2-0052" title="VerhammeKM , DielemanJP , vanWijkMA , BoschJL , StrickerBH , SturkenboomMC . Low incidence of acute urinary retention in the general male population: the triumph project. European Urology2005;47(4):494‐8. ">Verhamme 2005</a>). This rises to 17 to 25 in 1000 man‐years in men with lower urinary tract symptoms (LUTS) presumed secondary to benign prostatic enlargement (BPE) (<a href="./references#CD006744-bbs2-0021" title="BarryMJ , Fowler JrFJ , BinL , Pitts IIIJC , HarrisCJ , Mulley JrAG . The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology1997;157:10‐4, discussion 14‐5. ">Barry 1997</a>; <a href="./references#CD006744-bbs2-0038" title="McConnelJD , BruskewitzR , WalshP , AndrioleG , LieberM , HoltgreweHL , et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long‐term efficacy and safety study group. New England Journal of Medicine1998;338:557‐63. ">McConnell 1998</a>; <a href="./references#CD006744-bbs2-0047" title="RoehrbornCG , BruskewitzR , NickelGC , GlickmanS , CoxC , AndersonR , et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. European Urology2000;37:528‐36. ">Roerborn 2000</a>). It has been claimed that emergency admissions due to retention have a larger adverse impact on patients' health‐related quality of life than emergency admissions for renal colic or elective admission for surgery for LUTS or BPE. This is mainly due to the higher number of investigations and recurrent emergency attendances in the acute urinary retention group compared to the other two groups (<a href="./references#CD006744-bbs2-0051" title="ThomasK , OadesG , Taylor‐HayC , KirbyRS . Acute urinary retention: what is the impact on patients' quality of life?. British Journal of Urology International2005;95(1):72‐6. ">Thomas 2005</a>). </p> <p>The causes of acute urinary retention can be classified into three categories. The first one is characterised by any condition that causes an increased resistance to urinary flow (for example, BPE, bladder neck stenosis, urethral stricture). The second category is characterised by weakness of the detrusor muscle or interruption of the sensory bladder innervation (for example, spinal cord injuries, neurological disorders such as multiple sclerosis). The third category is caused by any event leading to bladder overdistention (for example, following surgery or as a side effect of drug treatment) (<a href="./references#CD006744-bbs2-0028" title="EmbertonM , AnsonK . Acute urinary retention in men: an age old problem. BMJ1999;318:921‐5. ">Emberton 1999</a>). Retention is also commonly associated with urinary tract infection. </p> <p>The definitive treatment depends on the underlying cause. The principal aim of treatment is to restore spontaneous voiding without the need for re‐catheterisation and, by doing so, avoiding the risk of catheter‐related complications (such as causing a false urethral passage, infection, pain, haematuria (blood in the urine), urethral stricture formation) and worsening renal function (acute or chronic renal failure) to improve quality of life. Catheters are either introduced by the transurethral or suprapubic route and can be used short term, long term or intermittently. </p> </section> <section id="CD006744-sec-0032"> <h3 class="title" id="CD006744-sec-0032">Description of the intervention</h3> <p>There are three approaches to treatment once symptoms have been controlled by bladder catheterisation. </p> <p> <ol id="CD006744-list-0001"> <li> <p>The first is early surgery, such as transurethral resection of the prostate, within a few days or semi‐elective within a few weeks of the first episode of retention. Surgery carries the risk of bleeding, infection, retrograde ejaculation, erectile dysfunction, urinary incontinence, treatment failure and recurrence of lower urinary tract symptoms (<a href="./references#CD006744-bbs2-0042" title="OmarMI , LamTB , AlexanderCE , GrahamJ , MamoulakisC , ImamuraM , et al. Systematic review and meta‐analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU International2014; Vol. 113, issue 1:24–35. [DOI: 10.1111/bju.12281] ">Omar 2014</a>). </p> </li> <li> <p>The second approach is long‐term catheterisation, using either an in‐dwelling transurethral or suprapubic catheter, or intermittent catheterisation. This approach has disadvantages such as urinary tract infection (<a href="./references#CD006744-bbs2-0041" title="Niël‐WeiseBS , van denBroekPJ . Urinary catheter policies for long‐term bladder drainage. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD004201.pub2] ">Niël‐Weise 2005</a>). </p> </li> <li> <p>The third option is to remove the catheter again to see whether normal micturition resumes, a trial without catheter (TWOC). This can be done in an ambulant or in‐patient hospital setting. </p> </li> </ol> </p> <p>Success rates reported for TWOC in observational studies range from 23% to 28% (<a href="./references#CD006744-bbs2-0040" title="MurrayK , MasseyA , FeneleyRC . Acute urinary retention ‐ a urodynamic assessment. British Journal of Urology1984;56:468‐73. ">Murray 1984</a>; <a href="./references#CD006744-bbs2-0049" title="TaubeM , GajrajH . Trial without catheter following acute retention of urine. British Journal of Urology1989;63(2):180‐2. ">Taube 1989a</a>). Failure requires re‐catheterisation and re‐assessment of future management options, such as prostate surgery or long‐term catheterisation. There are advantages both for the patient and healthcare system from a successful trial period without a catheter. Apart from not having to spend time with a catheter at home, successful resumption of voiding could mean delaying or ideally avoiding the need for surgery. It has also been shown that surgery, where necessary, is safer in the absence of an indwelling catheter (<a href="./references#CD006744-bbs2-0043" title="PickardR , EmbertonM , NealDE . The management of men with acute urinary retention. British Journal of Urology1998;81:712‐20. ">Pickard 1998</a>). </p> </section> <section id="CD006744-sec-0033"> <h3 class="title" id="CD006744-sec-0033">How the intervention might work</h3> <p>Any intervention which aims to increase the rate of successful TWOC following an acute urinary retention episode is considered potentially beneficial. Alpha1‐adrenoreceptors are highly prevalent in the prostate and bladder neck (<a href="./references#CD006744-bbs2-0025" title="CaineM , RazS , ZieglerM . Adrenergic and cholinergic receptors in the human prostate capsule and bladder neck. British Journal of Urology1975;47:193. ">Caine 1975</a>; <a href="./references#CD006744-bbs2-0027" title="CaineM , SchugerL . The capsule in benign prostatic hypertrophy. Department of Health and Human Services, National Institute of Health Publication1987;87‐2881:221. ">Caine 1987</a>). The principle behind the use of alpha1‐adrenoreceptor antagonists (alpha1 blockers) is that they reduce prostatic smooth muscle tonus and thus resistance to urinary flow (<a href="./references#CD006744-bbs2-0029" title="FultonB , WagstaffAJ , SorkinEM . Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs1995;49:295‐320. ">Fulton 1995</a>). This should result in an improvement of urinary symptoms. Caine and colleagues suggested that alpha blockers could improve the chances of successful TWOC, assuming there is adequate detrusor function (<a href="./references#CD006744-bbs2-0026" title="CaineM , PfauA , PerlbergS . The use of alpha‐adrenergic blockers in benign prostatic obstruction. British Journal of Urology1976;48:255‐63. ">Caine 1976</a>). However, their wide use at that time was restricted mainly because of cardiovascular side effects. Functionally more uroselective agents have been developed. Alpha1 blockers such as alfuzosin, doxazosin, indoramin, prazosin, silodosin, tamsulosin and terazosin are commonly used as first‐line treatment for lower urinary tract symptoms associated with BPE. </p> <p>Despite their greater selectivity, alpha1 blockers can still interact with many other drugs. Their main pharmacological adverse effect, apart from retrograde ejaculation, remains an additive or enhancing hypotensive effect especially when used with other antihypertensive drugs. Known adverse effects include drowsiness, (postural) hypotension, syncope, asthenia, depression, headache, dry mouth, nausea, vomiting, diarrhoea, constipation (gastro‐intestinal disturbances), oedema, blurred vision, rhinitis, erectile disorders (including priapism), tachycardia and palpitations. They should, therefore, be avoided in patients with a history of postural hypotension and micturition syncope. Patients on antihypertensive treatment may require reduced dosage. Alpha blockers are also associated with hypersensitivity reactions including rash, pruritus and angioedema. Caution is advised in elderly patients and those with hepatic or severe renal impairment. Caution is also in elderly people undergoing cataract surgery as there is risk of intra‐operative floppy iris syndrome (most strongly associated with tamsulosin) (<a href="./references#CD006744-bbs2-0024" title="Joint Formulary Committee. British National Formulary December 2013. London: Published jointly by BMJ Group and Pharmaceutical Press, 2013. Available at: http://www.bnf.org. ">BNF December 2013</a>). </p> </section> <section id="CD006744-sec-0034"> <h3 class="title" id="CD006744-sec-0034">Why it is important to do this review</h3> <p>A systematic review of the available evidence from randomised controlled trials (RCTs), periodically updated, is needed to find out whether alpha blockers improve the chances of successful TWOC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006744-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006744-sec-0035"></div> <p>To assess the effectiveness of alpha blockers on successful resumption of micturition following removal of a urethral urinary catheter after an episode of acute urinary retention in men. In the absence of internationally agreed outcome measures for the success of a trial without catheter (TWOC), success was defined as the return to satisfactory voiding without need for re‐catheterisation within 24 hours. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006744-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006744-sec-0036"></div> <section id="CD006744-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006744-sec-0038"> <h4 class="title">Types of studies</h4> <p>All randomised and quasi‐randomised controlled trials (<a href="./references#CD006744-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) of alpha blockers for TWOC after acute urinary retention in men. </p> </section> <section id="CD006744-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adult men of any age who needed to be catheterised transurethrally because of an episode of acute urinary retention. </p> </section> <section id="CD006744-sec-0040"> <h4 class="title">Types of interventions</h4> <p>At least one trial group managed with alpha blockers versus any other type of management. Other types of management included placebo or no treatment, or other active treatments such as another alpha blocker. </p> <p>The following comparisons were addressed:</p> <p> <ol id="CD006744-list-0002"> <li> <p>an alpha blocker versus placebo or no treatment;</p> </li> <li> <p>one alpha blocker versus another alpha blocker;</p> </li> <li> <p>an alpha blocker versus another active treatment.</p> </li> </ol> </p> </section> <section id="CD006744-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD006744-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD006744-list-0003"> <li> <p>Ability to void spontaneously after TWOC without the need for re‐catheterisation</p> </li> <li> <p>Incidence of recurrent urinary retention</p> </li> <li> <p>Need for prostatic surgery</p> </li> <li> <p>Adverse effects of alpha blockers</p> </li> <li> <p>Condition‐specific quality of life measures (e.g. IPSS (International Prostate Symptom Score)) (<a href="./references#CD006744-bbs2-0022" title="Batista‐MirandaJE , Regalado ParejaR , Huguet PérezJ , Montlleo SánchezM , Araño BertranP . The use of the IPSS questionnaire in surgical patients. International Prostatic Symptom Score. Actas Urol Esp1995;19(3):227‐33. ">Batista‐Miranda 1995</a>) </p> </li> <li> <p>Cost effectiveness</p> </li> </ol> </p> <p>These six outcomes were considered 'critical' for the purpose of analysis using GRADE.</p> </section> <section id="CD006744-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006744-list-0004"> <li> <p>Drop‐out/discontinuation rates (due to adverse effects or lack of therapeutic effect)</p> </li> <li> <p>Persistent lower urinary tract symptoms (LUTS)</p> </li> <li> <p>Quality of life (QoL) (psychological)</p> </li> <li> <p>General quality of life health measures (e.g. SF12, SF36 questionnaires)</p> </li> </ol> </p> <section id="CD006744-sec-0044"> <h6 class="title">Quality of evidence</h6> <p>The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (<a href="./references#CD006744-bbs2-0030" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011</a>; <a href="./references#CD006744-bbs2-0031" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. ">Guyatt 2011a</a>; <a href="./references#CD006744-bbs2-0032" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing Summary of Findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. ">Guyatt 2013a</a>; <a href="./references#CD006744-bbs2-0033" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173‐83. ">Guyatt 2013b</a>). The following five domains were assessed for evaluating the quality of evidence. </p> <p> <ol id="CD006744-list-0005"> <li> <p>Limitations of study design</p> </li> <li> <p>Inconsistency of results</p> </li> <li> <p>Indirectness of evidence</p> </li> <li> <p>Imprecision of measurements</p> </li> <li> <p>Publication bias</p> </li> </ol> </p> <p>The primary outcomes listed above were categorised as 'critical' for decision‐making from the male patient's perspective: the remaining secondary outcomes were categorised as 'important' or 'not important'. Evidence related to outcomes deemed 'critical' was then rated as high, moderate, low or very low quality. This rating indicates confidence in the accuracy of the measured effect of intervention compared to the true effect. The quality of evidence was downgraded if the randomisation process (random sequence generation and allocation concealment) of the trial was considered to be inadequate and/or if the effect estimate crossed the line of 'no effect' on either side by 25% or 50% (i.e. an effect estimate with a wide confidence interval). Further reasons to downgrade were if findings between trials were inconsistent or if trials measured outcomes not directly corresponding to the pre‐specified review outcomes. Publication bias was only assessed if there were 10 or more trials. The GRADE working group recommended including up to seven critical outcomes in a systematic review. Quality of evidence was assessed for all primary outcomes if reported (<a href="./references#CD006744-bbs2-0030" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011</a>; <a href="./references#CD006744-bbs2-0031" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. ">Guyatt 2011a</a>; <a href="./references#CD006744-bbs2-0032" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing Summary of Findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. ">Guyatt 2013a</a>; <a href="./references#CD006744-bbs2-0033" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173‐83. ">Guyatt 2013b</a>). </p> </section> </section> </section> </section> <section id="CD006744-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not impose any language or other restrictions on the searches.</p> <section id="CD006744-sec-0046"> <h4 class="title">Electronic searches</h4> <p>This review has drawn on the search strategy developed for the Cochrane Incontinence Review Group. Relevant trials were identified from the Group's Specialised Register of controlled trials which is described, along with the group search strategy, under the Incontinence Group's <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/INCONT/frame.html" target="_blank">module</a> in <i>The Cochrane Library</i>. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE in process, and handsearching of journals and conference proceedings. The Incontinence Group Specialised Register was searched using the Group's own keyword system. The date of the last search was 9 October 2013. </p> <p>The terms used to search the Incontinence Group Specialised Register are given below.</p> <p>({DESIGN.CCT*} OR {DESIGN.RCT*})</p> <p>AND</p> <p>({INTVENT.MECH.CATH.TrialOffCatheter.prostate.} OR {INTVENT.MECH.CATH.trialWithoutCath.})</p> <p>(All searches were of the keyword field of <a href="./references#CD006744-bbs2-0046" title="Reference Manager Professional Edition Version 12. New York: Thomson Reuters2012. ">Reference Manager 2012</a>). </p> <p>For the current version of the review the following databases were also searched (all on OVID SP), the date of the last search for all except CENTRAL was 4 June 2013. The search terms are given in <a href="./appendices#CD006744-sec-0099">Appendix 1</a>: </p> <p> <ul id="CD006744-list-0006"> <li> <p><b>CENTRAL</b> (2013, Issue 5) was last searched on 5 June 2013 </p> </li> <li> <p><b>MEDLINE</b> 1946 to May Week 4 2013 </p> </li> <li> <p><b>MEDLINE in Process</b> (covering to 3 June 2013) </p> </li> <li> <p><b>EMBASE Classic</b> and<b>EMBASE</b> 1947 to 2013 Week 22 </p> </li> </ul> </p> <p>For the original version of this review (<a href="./references#CD006744-bbs2-0053" title="ZeifHJ , SubramonianK . Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006744.pub2] ">Zeif 2009</a>) extra, specific searches were performed. For details of this search please see <a href="./appendices#CD006744-sec-0100">Appendix 2</a>. </p> </section> <section id="CD006744-sec-0047"> <h4 class="title">Searching other resources</h4> <p>The reference lists of relevant articles were checked for other potentially relevant trial reports. </p> </section> </section> <section id="CD006744-sec-0048"> <h3 class="title" id="CD006744-sec-0048">Data collection and analysis</h3> <section id="CD006744-sec-0049"> <h4 class="title">Selection of studies</h4> <p>Only randomised or quasi‐randomised trials were included in this systematic review. Two review authors (EF and MO) independently examined all the citations and abstracts derived from the search strategy. Full reports of potentially relevant trials were then retrieved and examined independently for eligibility in the same manner. Review authors were not blinded to the names of the trials' authors, institutions or the journals. We contacted authors of trials under consideration for additional information when required. Trials in languages other than English were translated as appropriate. Any disagreement about trial selection and inclusion was resolved by discussion. An independent judgment was sought where disagreement persisted. Excluded studies considered formally for this review were also listed along with reasons for their exclusion. Studies were excluded from the review if they were not randomised or quasi‐randomised controlled trials of treatment with alpha blockers for urinary retention, or if they made comparisons other than those pre‐specified. Trials were also excluded if the participants were not relevant. </p> <p>The process of trial selection is documented in a PRISMA flow chart (<a href="#CD006744-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006744-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD006744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD006744-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EF and MO) independently extracted data from included trials using a standardised form. Any differences of opinion relating to study inclusion, methodological flaws or data extraction were resolved by discussion among the review authors and, when necessary, were referred for independent arbitration. Trial authors were contacted when there was insufficient information. All data entry was done using Review Manager software (RevMan 5.2). Quality of evidence was assessed by adopting GRADE approach by two review authors (EF and MO) using GRADEpro software. Data from included trials were processed according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006744-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006744-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The Cochrane 'Risk of bias' assessment tool (<a href="./references#CD006744-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) was used to assess the risk of bias in included trials. Domains of bias included the following. </p> <p> <ul id="CD006744-list-0007"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants or staff</p> </li> <li> <p>Blinding of outcome assessors</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting of outcomes</p> </li> <li> <p>Any other potential sources of bias</p> </li> </ul> </p> <p>These domains were independently assessed by two review authors. Any difference of opinion was resolved by discussion. Where disagreement persisted, a third party was consulted. </p> </section> <section id="CD006744-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>The analyses in this systematic review were based upon available data from all included trials relevant to the comparisons and outcomes being studied. When trials were reported in multiple publications, only the most current or complete data were included for each outcome. When appropriate, meta‐analysis was performed using a fixed‐effect model for calculation of pooled estimates and their 95% confidence intervals (CI). </p> <p>For categorical outcomes, the number of participants reporting an outcome was related to the number at risk in each group to derive the risk ratio (RR). If continuous variables had been identified, we planned to use the mean and standard deviation to derive a mean difference. For similar outcomes reported using different scales, the standard mean difference (SMD) would have been calculated. When data used to calculate RRs were unavailable, the most detailed available numerical data were used to calculate actual numbers or mean and standard deviations (e.g. P values). Differences between trials were further investigated when significant heterogeneity was found or appeared obvious from visual inspection of the results. </p> </section> <section id="CD006744-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>Analysis of the primary outcome was per man randomised.</p> </section> <section id="CD006744-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>As far as possible, data were analysed on an "intention‐to‐treat" basis, so that participants were analysed in the groups to which they were originally randomised. Trials which did not do this were considered for exclusion. In the case of missing data, attempts were made to obtain these from the original trialists (see <a href="#CD006744-sec-0096">Acknowledgements</a>). Data were reported as shown in the trials if this was possible except in the case of evidence of differential loss to follow‐up, for which imputation of missing data was considered. </p> </section> <section id="CD006744-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>Only trials deemed clinically similar were combined. Heterogeneity between trials was evaluated by visual inspection of forest plots and the I<sup>2</sup> test. Thresholds for interpretation of the I<sup>2</sup> test were defined according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006744-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006744-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>In light of the difficulties associated with the detection of, and correction for, publication bias and other biases, the authors strived to minimise their impact by ensuring a fully comprehensive search strategy was used and by monitoring for duplication of data. </p> </section> <section id="CD006744-sec-0057"> <h4 class="title">Data synthesis</h4> <p>Trials were combined for analysis of similar interventions based upon clinical criteria.</p> </section> <section id="CD006744-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Data were subgrouped by the type of alpha blocker received by participants.</p> <p> <ul id="CD006744-list-0008"> <li> <p>Alfuzosin</p> </li> <li> <p>Tamsulosin</p> </li> <li> <p>Doxazosin</p> </li> <li> <p>Silodosin</p> </li> </ul> </p> <p>Test for subgroup differences was carried out with Chi<sup>2</sup> and I<sup>2</sup> tests. </p> <p>If heterogeneity between trials was evident, we planned investigation to identify its causes. </p> </section> <section id="CD006744-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to determine the effects of including or excluding trials at high risk of bias, but this was not possible due to lack of trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006744-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006744-sec-0060"></div> <section id="CD006744-sec-0061"> <h3 class="title">Description of studies</h3> <p>Full characteristics of the trials are presented in the tables '<a href="./references#CD006744-sec-0114" title="">Characteristics of included studies</a>'' and '<a href="./references#CD006744-sec-0115" title="">Characteristics of excluded studies</a>'. </p> <section id="CD006744-sec-0062"> <h4 class="title">Results of the search</h4> <p>The literature search resulted in 34 records to assess. The flow of literature through the assessment process is shown in the PRISMA flowchart (<a href="#CD006744-fig-0001">Figure 1</a>). </p> </section> <section id="CD006744-sec-0063"> <h4 class="title">Included studies</h4> <p>Nine randomised controlled trials were included in the systematic review. The trials involved a total of 1044 men who received either an alpha blocker, placebo or no treatment for one to three days in six trials, a maximum of eight days in one trial and 32 days in the other trial, before trial without catheter (TWOC) following an acute urinary retention episode. The number of study participants in each trial ranged from 44 to 360. The trials were conducted in China, India, Singapore, Spain, the UK and USA. </p> <p> <ul id="CD006744-list-0009"> <li> <p>Five trials compared alfuzosin versus placebo (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). </p> </li> <li> <p>Two trials compared tamsulosin versus placebo (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>). </p> </li> <li> <p>One trial compared tamsulosin versus no treatment (<a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>). </p> </li> <li> <p>One trial compared doxazosin versus no treatment (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>). </p> </li> <li> <p>One trial compared silodosin versus placebo (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>). </p> </li> </ul> </p> <p>The primary endpoint of what constitutes successful TWOC was defined differently by the trialists, reflecting the lack of internationally agreed outcome measures. </p> <p> <ul id="CD006744-list-0010"> <li> <p><a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a> and <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a> defined it simply as the return to satisfactory voiding after catheter removal. </p> </li> <li> <p>No definition was given by <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a> and <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>. </p> </li> <li> <p><a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a> defined successful TWOC as the return to satisfactory voiding without a need for re‐catheterisation within 24 hours. </p> </li> <li> <p>Shah and colleagues (<a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>) defined it as the ability to void with a residual volume of 200 mL or less </p> </li> <li> <p><a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a> used a flow rate greater than 5 mL/sec with a voided volume of greater than 100 mL and residual volume of 200 mL or less. </p> </li> <li> <p><a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a> and <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a> defined it as successful voiding with a post void residual volume of less than 150 mL. </p> </li> </ul> </p> <p>The trials used a variety of outcome measures. Apart from successful TWOC, these included:</p> <p> <ul id="CD006744-list-0011"> <li> <p>prevention of recurrent urinary retention after successful TWOC (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>); </p> </li> <li> <p>need for prostatic surgery (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>); </p> </li> <li> <p>persistent lower urinary tract symptoms (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>); </p> </li> <li> <p>post‐void residual volumes (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>); </p> </li> <li> <p>condition‐specific QoL (IPSS scores) (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>); </p> </li> <li> <p>alpha blocker adverse effects (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>); </p> </li> <li> <p>alpha blocker serious adverse effects (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>); </p> </li> <li> <p>maximum urinary flow rate (Qmax) (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>); </p> </li> <li> <p>drop‐out rates (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). </p> </li> </ul> </p> <p>None of the eligible trials addressed outcome measures such as spontaneously voided volume, cost effectiveness, improvement in QoL (other than condition‐specific QoL as assessed by IPSS score) or general health measures (for example SF12 or SF36 questionnaires). </p> </section> <section id="CD006744-sec-0064"> <h4 class="title">Excluded studies</h4> <p>Nine studies were excluded (<a href="./references#CD006744-bbs2-0010" title="JooKJ , ChoiJB , KimYS , KimH , ParkHS , LeeW , et al. Effect of tamsulosin in benign prostatic hyperplasia patients who were treated with spinal anesthesia: preventing the acute urinary retention (Abstract number 294). Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 2008 Oct 20‐24, Cairo, Egypt. 2008. ">Joo 2008</a>; <a href="./references#CD006744-bbs2-0011" title="KrausSR , DmochowskiR , AlboME , XuL , KliseSR , RoehrbornCG . Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourology &amp; Urodynamics2010;29(5):741‐7. ">Kraus 2010</a>; <a href="./references#CD006744-bbs2-0012" title="LimKB , WongMY , FooKT . The outcome of trial off catheter after acute retention of urine. Annals of the Academy of Medicine, Singapore1999;28(4):516‐8. ">Lim 1999</a>; <a href="./references#CD006744-bbs2-0013" title="LiuH , LiuP , MaoG , ChenG , WangB , QinX , et al. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double‐blind clinical trial. Urology2009;74(1):130‐6. ">Liu 2009</a>; <a href="./references#CD006744-bbs2-0014" title="Lorente GarinJA , CanisSD , ArangoTO , BielsaGO , CortadellasAR , GelabertMA . [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. [Spanish]. Actas Urologicas Espanolas2004;28(1):32‐7. [MEDLINE: 23480] ">Lorente 2004</a>; <a href="./references#CD006744-bbs2-0015" title="MartovAG , MaksimovVA , ErgakovDV , MiroshnikovVM , AsfandiiarovFR , KalashnikovES . [Tamsulosin administration for prophylaxis and treatment of stent‐related symptoms] [Russian]. Urologiia (Moscow, Russia)2010 Jan‐Feb;.(1):3‐8. ">Martov 2010</a>; <a href="./references#CD006744-bbs2-0016" title="McNeillAS , RizviS , ByrneDJ . Prostate size influences the outcome after presenting with acute urinary retention. BJU International2004;94(4):559‐62. ">McNeill 2004</a>; <a href="./references#CD006744-bbs2-0017" title="TaubeM , GajrajH . Trial without catheter following acute retention of urine [see comments]. British Journal of Urology1989;63(2):180‐2. ">Taube 1989b</a>; <a href="./references#CD006744-bbs2-0018" title="WangCJ , HuangSW , ChangCH . Effects of tamsulosin on lower urinary tract symptoms due to double‐J stent: a prospective study. Urologia Internationalis2009;83(1):66‐9. ">Wang 2009</a>). One study involved elective catheterisation prior to spinal surgery (<a href="./references#CD006744-bbs2-0010" title="JooKJ , ChoiJB , KimYS , KimH , ParkHS , LeeW , et al. Effect of tamsulosin in benign prostatic hyperplasia patients who were treated with spinal anesthesia: preventing the acute urinary retention (Abstract number 294). Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 2008 Oct 20‐24, Cairo, Egypt. 2008. ">Joo 2008</a>). Four studies did not involve use of a catheter (<a href="./references#CD006744-bbs2-0011" title="KrausSR , DmochowskiR , AlboME , XuL , KliseSR , RoehrbornCG . Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourology &amp; Urodynamics2010;29(5):741‐7. ">Kraus 2010</a>; <a href="./references#CD006744-bbs2-0013" title="LiuH , LiuP , MaoG , ChenG , WangB , QinX , et al. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double‐blind clinical trial. Urology2009;74(1):130‐6. ">Liu 2009</a>; <a href="./references#CD006744-bbs2-0015" title="MartovAG , MaksimovVA , ErgakovDV , MiroshnikovVM , AsfandiiarovFR , KalashnikovES . [Tamsulosin administration for prophylaxis and treatment of stent‐related symptoms] [Russian]. Urologiia (Moscow, Russia)2010 Jan‐Feb;.(1):3‐8. ">Martov 2010</a>; <a href="./references#CD006744-bbs2-0018" title="WangCJ , HuangSW , ChangCH . Effects of tamsulosin on lower urinary tract symptoms due to double‐J stent: a prospective study. Urologia Internationalis2009;83(1):66‐9. ">Wang 2009</a>). Two studies addressed TWOC in patients without any alpha blocker or other treatment (<a href="./references#CD006744-bbs2-0012" title="LimKB , WongMY , FooKT . The outcome of trial off catheter after acute retention of urine. Annals of the Academy of Medicine, Singapore1999;28(4):516‐8. ">Lim 1999</a>; <a href="./references#CD006744-bbs2-0017" title="TaubeM , GajrajH . Trial without catheter following acute retention of urine [see comments]. British Journal of Urology1989;63(2):180‐2. ">Taube 1989b</a>), and one study used increasing dosages of alpha blocker in failed TWOC patients (<a href="./references#CD006744-bbs2-0014" title="Lorente GarinJA , CanisSD , ArangoTO , BielsaGO , CortadellasAR , GelabertMA . [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. [Spanish]. Actas Urologicas Espanolas2004;28(1):32‐7. [MEDLINE: 23480] ">Lorente 2004</a>). One study involved long‐term follow‐up of patients who had previously had successful TWOC (<a href="./references#CD006744-bbs2-0016" title="McNeillAS , RizviS , ByrneDJ . Prostate size influences the outcome after presenting with acute urinary retention. BJU International2004;94(4):559‐62. ">McNeill 2004</a>). </p> <p>A 2006 report detailing preliminary results of a trial had been originally included in this review but was superceded by a full publication (<a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). </p> <p>Lack of clarity regarding the process of randomisation in one trial (<a href="./references#CD006744-bbs2-0019" title="PerepanovaTS , KamalovAA , SinyuhinVN , GorohovAV , HazanPL , OrlovEV . Doxazosin (Kardura) with acute urinary retention due to benign prostatic hyperplasia. Urologiia2001;3:18‐20. ">Perepanova 2001</a>) meant that we needed to contact the trialists for additional information. This study was therefore moved into the '<a href="./references#CD006744-sec-0116" title="">Characteristics of studies awaiting classification</a>' section pending a response. </p> </section> </section> <section id="CD006744-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD006744-sec-0066"> <h4 class="title">Allocation</h4> <section id="CD006744-sec-0067"> <h5 class="title">Random sequence generation</h5> <p>Four of the included trials clearly described the method of randomisation. These were done by computer‐based randomisation in three trials (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) and in one trial by a 'centrally established randomization list' (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>). Four trials did not adequately specify their methods of randomisation (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>), and one study (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) was deemed high risk (quasi‐randomised) due to the allocation of patients by year of birth (odd years versus even). </p> </section> <section id="CD006744-sec-0068"> <h5 class="title">Concealment of allocation</h5> <p>Methods of allocation concealment were inadequately described in six of the included trials (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>). One low risk study (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>) used a 'sealed copy of the code' to conceal randomisation and another stated that allocation was blinded (<a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). One study (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) was deemed high risk as allocation concealment was judged to be highly unlikely given the method of randomisation (described above, quasi‐randomised). </p> </section> </section> <section id="CD006744-sec-0069"> <h4 class="title">Blinding</h4> <section id="CD006744-sec-0070"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Blinding of participants and personnel was adequately described in four trials (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>), one of which (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>) stating that a central pharmacy 'packaged the SR alfuzosin and placebo to appear identical'. This aspect of study design was not adequately described in a further four trials (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>), and in one trial (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) was deemed to be high risk due to the method of randomisation (described earlier, quasi‐randomised). </p> </section> <section id="CD006744-sec-0071"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>None of the included trials (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) gave details of blinding of outcome assessment. Therefore all these trials were judged as "unclear" risk of bias for this domain. </p> </section> </section> <section id="CD006744-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Seven of the included trials were classified as low risk for incomplete outcome data (<a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). It was unclear in one trial (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>) if data were complete due to lack of detail in tables of analysis. One trial was classified high risk due to incomplete data for three patients (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>). </p> </section> <section id="CD006744-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Due to lack of availability of the study protocols, it was not clear if selective reporting was present in any of the included trials (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). </p> </section> <section id="CD006744-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>Two trials (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) were classified as low risk of other bias, two trials (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>) as unclear risk, and five trials (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>) as high risk. Both <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a> and <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a> had comparable groups at baseline, had obtained ethical approval and informed consent and had a low withdrawal rate/no withdrawals at all and were judged at low risk of bias. The trials deemed unclear risk did not adequately explain such aspects of study design. All trials deemed high risk received financial support from pharmaceutical companies. Further reasons for this classification included lack of baseline comparability in trials groups (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>), lack of justification for reporting both intention‐to‐treat and per‐protocol analyses (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>), and inconsistencies in description of trial interventions (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>). </p> <p>Detailed results of the 'Risk of bias' assessment are provided in <a href="#CD006744-fig-0002">Figure 2</a> and <a href="#CD006744-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006744-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006744-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> <section id="CD006744-sec-0075"> <h3 class="title" id="CD006744-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD006744-tbl-0001"><b>Summary of findings for the main comparison</b> Alpha blocker versus placebo or control for acute urinary retention in adult men</a> </p> <p>Nine randomised controlled trials met the inclusion criteria for this review (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). All compared alpha blockers versus placebo. Five trials tested alfuzosin (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>), three trials tested tamsulosin (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>), one trial tested doxazosin (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) and one trial tested silodosin (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>). </p> <section id="CD006744-sec-0076"> <h4 class="title">Primary outcomes</h4> <p>We applied GRADE to all these primary outcomes and the results are summarised in the <a href="./full#CD006744-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD006744-sec-0077"> <h5 class="title">Ability to void spontaneously after trial without catheter (TWOC)</h5> <p>All nine trials reported this outcome (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0002" title="HuaLX , WuHF , SuiYG , ChenSG , XuZQ , ZhangW , et al. [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. [Chinese]. Zhong Hua Nan Ke Xue2003;9(7):510‐1. [23479] ">Hua 2003</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>). There was moderate quality evidence that the usage of alpha blockers was better compared to placebo (366/608, 60.2% of men using an alpha blocker were able to void spontaneously after catheter removal compared with 185/486, 38.1% using placebo, risk ratio (RR) 1.55, 95% confidence interval (CI) 1.36 to 1.76) (<a href="./references#CD006744-fig-0004" title="">Analysis 1.1</a>). </p> <p>On subgroup analysis based upon individual drugs, three types of alpha blockers were statistically significantly better than placebo: alfuzosin RR 1.40 (95% CI 1.19 to 1.64); tamsulosin RR 1.97 (95% CI 1.49 to 2.59); and silodosin RR 2.09 (1.26 to 3.48) (<a href="./references#CD006744-fig-0004" title="">Analysis 1.1</a>). The only trial to investigate doxazosin versus no medication (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) did not show a statistically significant difference (RR 1.09, 0.66 to 1.81, <a href="./references#CD006744-fig-0004" title="">Analysis 1.1</a>.3), but the confidence interval was wide and the trial was small. </p> </section> <section id="CD006744-sec-0078"> <h5 class="title">Incidence of recurrent acute urinary retention</h5> <p>Eight trials reported this outcome (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). There was moderate quality evidence that alpha blockers were effective in reducing the chance of recurrent urinary retention (204/573, 35.6% of men had a further episode of retention after alpha blocker use compared with 228/450, 50.7% after control, RR 0.69, 95% CI 0.60 to 0.79) (<a href="./references#CD006744-fig-0005" title="">Analysis 1.2</a>). </p> <p>On subgroup analysis based upon individual drugs, statistically significant differences were found to favour three of the drugs trialled (alfuzosin: RR 0.72, 95% CI 0.60 to 0.85; tamsulosin: RR 0.66, 95% CI 0.50 to 0.87; silodosin: RR 0.37, 95% CI 0.18 to 0.74). Only one trial (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>) investigated doxazosin and found no difference compared with patients who received no treatment, though the confidence intervals were wide (RR 0.98, 95% CI 0.65 to 1.48) </p> <p>Three other trials (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>;<a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) reported recurrent retention (relapse) after successful TWOC but this was carried out during the second phases of the trials after both successful alpha blocker and placebo participants were either re‐randomised or continued on alpha blocker treatment. Therefore, these data could not be used for analysis in this review. </p> </section> <section id="CD006744-sec-0079"> <h5 class="title">Need for prostatic surgery</h5> <p>Although reported in three trials (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>), this outcome measure could not be assessed due to the fact that participants of both the alpha blocker and placebo groups were pooled together in one group following successful TWOC and either randomised again (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>), openly followed up (<a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>) or continued (or commenced) on alpha blocker treatment (<a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>). </p> </section> <section id="CD006744-sec-0080"> <h5 class="title">Adverse effects of alpha blockers</h5> <p>Adverse effects described included dizziness, somnolence, fainting, headache, postural hypotension or hypotension, malaise, retrograde ejaculation and syncope. Five trials (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) reported this outcome (<a href="./references#CD006744-fig-0006" title="">Analysis 1.3</a>). No statistically significant difference was found in the incidence of adverse effects between alpha blockers and control overall (RR 1.19, 95% CI 0.75 to 1.89), with non‐significant findings also on subgroup analysis (alfuzosin: RR 0.91, 95% CI 0.53 to 1.54; tamsulosin: RR 2.71, 95% CI 0.90 to 8.14); doxazosin: RR 3.13, 95% CI 0.13 to 73.01, though this evidence was of low quality. </p> </section> <section id="CD006744-sec-0081"> <h5 class="title">Serious adverse effects of alpha blockers</h5> <p>Only one trial (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>) mentioned serious alpha blocker adverse effects but did not specify what constituted a 'serious' effect. The number of events was small (3/238 with alfuzosin versus 2/122 with placebo) and the difference was not statistically significant (RR 0.77, 95% CI 0.13 to 4.54) (<a href="./references#CD006744-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD006744-sec-0082"> <h5 class="title">Improvement in condition‐specific QoL (IPSS and bother score)</h5> <p>Two trials (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>) reported IPSS scores. </p> <p> <ul id="CD006744-list-0012"> <li> <p>An improvement was described in mean IPSS score with alfuzosin treatment compared with placebo (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>) (IPSS: alpha blocker 8.75 versus placebo 11.45, P = 0.012; bother score: alpha blocker 1.66 versus placebo 2.27, P = 0.004), although these patients had been re‐randomised after a successful TWOC. </p> </li> <li> <p>Patients treated with silodosin (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>) showed an improvement in mean IPSS scores at TWOC (TWOC: silodosin 25.7 +/‐ 2.5 versus placebo 24.9 +/‐ 1.8, P = 0.02). </p> </li> </ul> </p> <p>In both trials, IPSS scores were only collected in those men who had a successful TWOC. These data were therefore not relevant to the analyses of this review, and the quality of evidence could not be estimated. </p> </section> <section id="CD006744-sec-0083"> <h5 class="title">Cost effectiveness</h5> <p>No trials reported any information about cost effectiveness.</p> </section> </section> <section id="CD006744-sec-0084"> <h4 class="title">Secondary outcomes:</h4> <p>The following secondary outcomes were reported in the included trials.</p> <section id="CD006744-sec-0085"> <h5 class="title">Drop‐out/discontinuation rates (due to adverse effects or lack of therapeutic effect)</h5> <p>Five trials described drop‐out rates due to alpha blocker side effects involving alfuzosin, tamsulosin and doxazosin (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). There were lower drop‐out rates for placebo compared to alpha blocker treatment with a statistically significant outcome in favour of placebo (RR 3.94, 95% CI 1.28 to 12.12) (<a href="./references#CD006744-fig-0008" title="">Analysis 1.5</a>). Subgroup analysis showed no statistically significant difference for individual drugs however (alfuzosin: RR 2.83, 95% CI 0.62 to 12.93; tamsulosin: RR 6.91, 95% CI 0.87 to 54.76; doxazosin: RR 3.13, 95% CI 0.13 to 73.01). </p> </section> <section id="CD006744-sec-0086"> <h5 class="title">Persistent lower urinary tract symptoms (LUTS)</h5> <p>In the second phase (re‐randomisation of successful TWOC patients) of a trial (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>), a significant improvement of LUTS was described with alpha blocker treatment compared with placebo at six months follow‐up (IPSS 8.75 versus 11.45, P = 0.012 ; bother score 1.66 versus 2.27, P = 0.004). Due to re‐randomisation, we could not use this data as part of our pre‐defined secondary outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006744-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006744-sec-0087"></div> <p>This systematic review suggests that some alpha blockers may help men by increasing the rate of successful trial without catheter (TWOC) after an acute urinary retention episode. However, the current evidence is limited in terms of the number of trials and participants. A major limitation of this review is the lack of standardisation of the definition of a successful TWOC. When is a TWOC considered successful? Does it depend on maximum flow rate, residual volume, or both? Or is it simply no need for re‐catheterisation within 24 hours? Does re‐catheterisation after two or three days following a successful TWOC constitute a failed trial or is it recurrent urinary retention, that is a new event? </p> <p>Costs and cost effectiveness of alpha blocker treatment is important for both patients and healthcare providers. It would probably make little sense if alpha blockers only delayed prostate surgery for a few months, with the added cost and distress of going back into retention. Because this outcome was not reported in the trials, this review was unable to answer whether alpha blockers before catheter removal are cost effective in this clinical scenario. A few trials tried to address these issues but we could not assess the information as part of a meta‐analysis because men had been treated both with the active drug and a placebo. A review of the literature showed one retrospective study from Belgium that evaluated costs for the first six months after a failed TWOC following a first episode of acute urinary retention (<a href="./references#CD006744-bbs2-0037" title="LamotteM , AnnemansL , LambertsG , MichielsenD , NicolasH , VanCanghP , et al. The cost of complicated acute urinary retention: a patient chart analysis in Belgium]. Revue Medicale de Liege2005;60(11):875‐81. ">Lamotte 2005</a>). No alpha blockers were used in the study, which came to the conclusion that delayed transurethral resection of the prostate (TURP) during a subsequent or scheduled hospitalisation was less expensive compared to TURP performed during the initial emergency hospital admission. </p> <p>A follow‐on study to <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a> examined whether use of alfuzosin during hospitalisation for acute urinary retention and for six months after successful TWOC was cost effective compared to placebo and immediate prostatectomy (<a href="./references#CD006744-bbs2-0020" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. ">Annemans 2005</a>). Alfuzosin treatment was associated with a lower rate of prostatectomy after hospital discharge following successful TWOC. Alfuzosin treatment generated cost savings of £349 relative to placebo and £892 relative to immediate prostatectomy (both statistically significant, P &lt; 0.05). However, this is limited evidence considering the possible implications of this important issue. </p> <p>Another unanswered question is how long alpha blockers should be continued after successful TWOC? If future trials reporting on longer‐term outcomes suggest that most men on alpha blockers end up having prostate surgery within one year, then this could lead to a change in management strategy where men could be listed for prostate surgery regardless of a successful TWOC. In order to answer these questions, rigorous well‐designed randomised controlled trials, which use the recommendations set out in the CONSORT statement and reporting all critical outcomes, are required. </p> <section id="CD006744-sec-0088"> <h3 class="title" id="CD006744-sec-0088">Summary of main results</h3> <p>The critical outcomes were assessed using the GRADE approach. There was moderate quality evidence that alpha blockers increase success rates of a trial without a catheter. There was low quality evidence that alpha blockers may reduce the risk of recurrent urinary retention. There was insufficient evidence to determine whether the use of alpha blockers reduces the need for prostatic surgery. The effects on QoL, cost effectiveness and recommended duration of alpha blocker treatment after successful trial without catheter remain unknown, as these outcomes were not reported. </p> </section> <section id="CD006744-sec-0089"> <h3 class="title" id="CD006744-sec-0089">Overall completeness and applicability of evidence</h3> <p>Four of the pre‐specified primary outcomes were reported. All of the included trials reported successful TWOC though only three trials addressed incidence of recurrent acute urinary retention directly (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>).Only one of these reported any useable data on long‐term outcomes according to original allocation status (<a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>). Other trials reported need for re‐catheterisation as a TWOC failure endpoint (<a href="./references#CD006744-bbs2-0001" title="AgrawalMS , YadavA , YadavH , SinghAK , LavaniaP , JaimanR . A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian Journal of Urology2009;25(4):474‐8. ">Agrawal 2009</a>; <a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0008" title="ShahT , PalitV , BiyaniS , ElmasryY , PuriR , FlanniganGM . Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology2002;42(4):323‐32. ">Shah 2002</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>). We therefore combined these data by considering need for re‐catheterisation following TWOC as a surrogate marker of relapse of acute urinary retention. </p> <p>Four trials also addressed the issue of adverse effects due to alpha blocker treatment ( <a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>), with one trial (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>) reporting serious (but undefined) adverse effects. Five trials reported drop out due to adverse effects (<a href="./references#CD006744-bbs2-0004" title="LucasMG , StephensonTP , NargundV . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International2005;95(3):354‐7. [23750] ">Lucas 2005</a>; <a href="./references#CD006744-bbs2-0005" title="McNeillSA , DaruwalaPD , MitchellID , ShearerMG , HargreaveTB . Sustained‐release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‐controlled. [comment]. BJU International1999;84(6):622‐7. ">McNeill 1999</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>; <a href="./references#CD006744-bbs2-0007" title="PrietoL , RomeroJ , LopezC , OrtizM , PachecoJJ . Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urologia Internationalis2008;81(1):66‐71. ">Prieto 2008</a>; <a href="./references#CD006744-bbs2-0009" title="TibungMJB , TiongHY , MacalalagM , LiewL , LiMK . Alfuzosin XL prior to trial off catheter after acute urinary retention: early results from a randomized, double‐blinded, placebo‐controlled trial. International Journal of Urology2006;13 Suppl 1:35. TiongHY , TibungMJ , MacalalagM , LiMK , ConsigliereD . Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urologia Internationalis2009;83(1):44‐8. ">Tiong 2009</a>) but these were rare (less than 5% of men on active treatment). </p> <p>A condition‐specific quality of life measure (IPSS score) was also reported by two trials (<a href="./references#CD006744-bbs2-0003" title="KumarS , TiwariPD , GanesamoniR , SinghSK . Prospective randomized placebo‐controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology2013;82(1):171‐5. ">Kumar 2013</a>; <a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>) but the data were only reported in men who had had a successful TWOC, so were not relevant to a comparison between the groups. Other generic measures of quality of life (e.g. SF36) were not reported by any of the included trials. </p> <p>None of the included trials reported useable data regarding the need for further surgery according to original allocation status. Similarly, other pre‐specified secondary outcomes including urinary flow rate, cost effectiveness or costs were not reported. The incidence of LUTS was reported in the second phase of one trial (<a href="./references#CD006744-bbs2-0006" title="AnnemansL , CleemputI , LamotteM , McNeillA , HargreaveT . The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6‐month analysis. BJU International2005;96:566‐71. McNeillSA , HargreaveTB , Members of the Alfaur Study Group 2004. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology2004;171(6 Pt 1):2316‐20. McNeillSA , HargreaveTB , RoehrbornCG , Alfaur Study Group 2005. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double‐blind placebo‐controlled study. Urology2005;65(1):83‐9, discussion 89‐90. ">McNeill 2005</a>), though again the data were not usable. </p> </section> <section id="CD006744-sec-0090"> <h3 class="title" id="CD006744-sec-0090">Quality of the evidence</h3> <p>The assessment of trial methodology is crucial in determining the quality of the estimated size of treatment effects of all interventions. In this review, methodological flaws of the included trials were assessed using the reports of the trials. Quality of reporting was therefore fundamental to our judgement of methodological quality and quality of effect estimates. None of the reported outcomes deemed 'critical' were assessed to be of high quality, with one outcome deemed moderate quality and two low quality. The quality of evidence of three of the 'critical' outcomes were not estimable. </p> </section> <section id="CD006744-sec-0091"> <h3 class="title" id="CD006744-sec-0091">Potential biases in the review process</h3> <p>Every effort was made to ensure adherence to the methodological framework set out in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> (<a href="./references#CD006744-bbs2-0035" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We were nevertheless mindful of potential biases which may enter into the review process and endeavoured to correct these where possible. We ensured that the entire process (such as abstract and full text screening) was done independently by two review authors. An independent third party was involved in case of disagreement in order to minimise potential bias in the review process. </p> </section> <section id="CD006744-sec-0092"> <h3 class="title" id="CD006744-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>The review authors are unaware of any similar review relating to the subject investigated.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006744-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD006744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha blocker versus placebo or control, Outcome 1 Ability to void spontaneously after TWOC without the need for re‐catheterisation." data-id="CD006744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Alpha blocker versus placebo or control, Outcome 1 Ability to void spontaneously after TWOC without the need for re‐catheterisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha blocker versus placebo or control, Outcome 2 Incidence of recurrent urinary retention." data-id="CD006744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Alpha blocker versus placebo or control, Outcome 2 Incidence of recurrent urinary retention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha blocker versus placebo or control, Outcome 3 Number with adverse effects due to alpha‐blocker treatment." data-id="CD006744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Alpha blocker versus placebo or control, Outcome 3 Number with adverse effects due to alpha‐blocker treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha blocker versus placebo or control, Outcome 4 Number with serious adverse effects due to alpha‐blocker treatment." data-id="CD006744-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Alpha blocker versus placebo or control, Outcome 4 Number with serious adverse effects due to alpha‐blocker treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006744-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/urn:x-wiley:14651858:media:CD006744:CD006744-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_t/tCD006744-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha blocker versus placebo or control, Outcome 5 Number of drop‐outs due to adverse effects of alpha blockers treatment." data-id="CD006744-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Alpha blocker versus placebo or control, Outcome 5 Number of drop‐outs due to adverse effects of alpha blockers treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/media/CDSR/CD006744/image_n/nCD006744-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006744-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blocker versus placebo or control for acute urinary retention in adult men</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alpha blocker versus placebo or control for acute urinary retention in adult men</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> acute urinary retention in adult men<br/> <b>Intervention:</b> Aalpha blocker versus placebo or control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aalpha blocker versus placebo or control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ability to void spontaneously after TWOC without the need for re‐catheterisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b> <br/> (1.36 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1044<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>582 per 1000</b> <br/> (509 to 666) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of recurrent urinary retention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.69</b> <br/> (0.60 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1023<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> <br/> (304 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for prostatic surgery</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Condition‐specific QoL</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost effectiveness</b> ‐ <b>not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number with adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.2</b> <br/> (0.74 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>657<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (55 to 145) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; QoL: quality of life; <b>TWOC</b>: trial without catheter </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Random sequence generation unclear in 4 studies and high risk in 1 study. Allocation concealment unclear in 6 studies and high risk in 1 study.<br/> <sup>2</sup> A minimum of ten trials are required to assess for publication bias.<br/> <sup>3</sup> Random sequence generation unclear in 3 studies and high risk in 1 study. Allocation concealment unclear in 5 studies and high risk in 1 study.<br/> <sup>4</sup> Wide 95% confidence interval: RR 1.20 (95% CI 0.74 to 1.95) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blocker versus placebo or control for acute urinary retention in adult men</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/full#CD006744-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006744-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha blocker versus placebo or control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Ability to void spontaneously after TWOC without the need for re‐catheterisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.36, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alfuzosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.19, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tamsulosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.49, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Doxazosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.66, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Silodosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.26, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of recurrent urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.60, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Alfuzosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tamsulosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.50, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Doxazosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Silodosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.18, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number with adverse effects due to alpha‐blocker treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.75, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alfuzosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tamsulosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.90, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Doxazosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.13, 73.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number with serious adverse effects due to alpha‐blocker treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Alfuzosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of drop‐outs due to adverse effects of alpha blockers treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.94 [1.28, 12.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Alfuzosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.62, 12.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tamsulosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.91 [0.87, 54.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Doxazosin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.13, 73.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha blocker versus placebo or control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006744.pub3/references#CD006744-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006744.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006744-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006744-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006744-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006744-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD006744-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006744\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006744\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006744\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006744\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006744.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006744.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006744.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006744.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006744.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715815209"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006744.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715815213"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006744.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d904f0a18f55f',t:'MTc0MDcxNTgxNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 